TY - JOUR T1 - COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021 JF - medRxiv DO - 10.1101/2021.09.15.21263613 SP - 2021.09.15.21263613 AU - Brechje de Gier AU - Marjolein Kooijman AU - Jeanet Kemmeren AU - Nicolette de Keizer AU - Dave Dongelmans AU - Senna C.J.L. van Iersel AU - Jan van de Kassteele AU - Stijn P. Andeweg AU - the RIVM COVID-19 epidemiology and surveillance team AU - Hester E. de Melker AU - Susan J. M. Hahné AU - Mirjam J. Knol AU - Susan van den Hof Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/17/2021.09.15.21263613.abstract N2 - The objective of this study was to estimate vaccine effectiveness (VE) against COVID-19 hospitalization and ICU admission, per period according to dominating SARS-CoV-2 variant (Alpha and Delta), per vaccine and per time since vaccination. To this end, data from the national COVID-19 vaccination register was added to the national register of COVID-19 hospitalizations. For the study period 4 April – 29 August 2021, 15,571 hospitalized people with COVID-19 were included in the analysis, of whom 887 (5.7%) were fully vaccinated. Incidence rates of hospitalizations and ICU admissions per age group and vaccination status were calculated, and VE was estimated as 1-incidence rate ratio, adjusted for calendar date and age group in a negative binomial regression model. VE against hospitalization for full vaccination was 94% (95%CI 93-95%) in the Alpha period and 95% (95%CI 94-95%) in the Delta period. The VE for full vaccination against ICU admission was 93% (95%CI 87-96%) in the Alpha period and 97% (95%CI 97-98%) in the Delta period. VE was high in all age groups and did not show waning with time since vaccination up to 20 weeks after full vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Dutch Ministry of Health, Welfare and Sports.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Centre for Clinical Expertise at the RIVM assessed the research proposal. They verified whether the work complies with the specific conditions as stated in the law for medical research involving human subjects (WMO), and were of the opinion that the research does not fulfill one or both of these conditions and therefore conclude it is exempted for further approval by the ethical research committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe primary data is not publicly available. Aggregated tables of these data are made available weekly at the website of the RIVM. ER -